UnitedHealth Group, the largest health insurer in the United States, announced on Tuesday the immediate resignation of chief executive Andrew Witty, who will be succeeded by chairman Stephen Hemsley in a surprise leadership reshuffle that underscores the deepening turbulence facing the healthcare behemoth.
Hemsley, who led the company from 2006 to 2017 and oversaw its rise into a multibillion-dollar enterprise spanning insurance, data analytics, and pharmacy benefits, will now resume executive responsibilities while retaining his role as chairman. UnitedHealth cited “personal reasons” for Witty’s departure, but the move comes after months of mounting investor pressure and operational upheaval.
In April, UnitedHealth delivered its first quarterly earnings miss in over 15 years and slashed its profit forecast for 2025 - a projection it has now suspended altogether, announcing today that it is withdrawing it. The company’s stock has lost over a third of its value since mid-April, wiping out nearly $190 billion in market capitalisation. The share price dropped a further 8% in premarket trading on Tuesday following the leadership news.
The abrupt transition marks a pivotal moment for UnitedHealth, which is grappling with the convergence of several damaging crises. These include a recent cyberattack on its technology arm, growing scrutiny from US federal agencies over its consolidation strategy, and public backlash following the December 2024 shooting of Brian Thompson, who had led the firm’s insurance division. The fallout from the executive’s death, and the company’s response to it, are now the subject of a shareholder lawsuit filed in federal court last week.
UnitedHealth is also contending with persistently higher-than-expected medical costs in its Medicare Advantage business - its most lucrative segment. The insurer said care utilization has continued to escalate, with new enrolees driving up claims beyond earlier projections. Rivals have experienced similar headwinds, but UnitedHealth’s revised guidance and sudden leadership shift have drawn particular investor alarm.
The company now says it expects a return to growth in 2026, though it has offered little concrete detail about its financial outlook in the interim.
In reinstating Hemsley, UnitedHealth appears to be leaning into continuity amid instability. During his previous tenure, Hemsley spearheaded the firm’s transformation from a conventional health insurer into a diversified healthcare conglomerate, one that integrated its own doctors, clinics, and data platforms under the Optum brand.
His return mirrors a trend seen at other major companies that turned to past executives in times of distress - Bob Iger at Disney and Howard Schultz at Starbucks, among others.
“Steve Hemsley brings a combination of strategic vision and deep operational focus that are highly valuable to our company,” said Michele Hooper, UnitedHealth’s lead independent director.
In a statement, Hemsley expressed appreciation for Witty’s stewardship “during some of the most challenging times any company has ever faced”, while reiterating his commitment to restoring UnitedHealth’s long-term growth trajectory of 13% to 16% annually.
Witty, who joined UnitedHealth in 2021 after leading GlaxoSmithKline, will remain with the company as a senior adviser. His leadership had been marked by an ambitious expansion of Optum and attempts to steer the company through intensifying regulatory scrutiny, but his tenure ultimately became defined by crisis management.
The shockwaves from UnitedHealth’s revised earnings and governance changes have rippled across the broader health insurance sector. Shares in Humana, CVS Health, and Elevance Health also dipped in early trading, as concerns mount over the sustainability of the Medicare Advantage model and government reimbursement rates.
UnitedHealth is currently under antitrust investigation by the US Department of Justice, with particular attention on whether its internal verticals - insuring patients while simultaneously paying its own providers - constitute anti-competitive behavior.
Meanwhile, the shareholder lawsuit accuses UnitedHealth’s leadership of withholding material information from investors in the wake of Thompson’s death, including how shifts in business practices to reduce claim denials may have undermined profit margins.
While Witty pointed to policy changes as a principal cause of the company’s April shortfall, investors remained unconvinced, triggering UnitedHealth’s largest single-day market loss in over 25 years.
As the firm looks to regroup under familiar leadership, the central challenge will be to reassert strategic clarity while confronting both legal and financial headwinds. Whether Hemsley can replicate his earlier success in a vastly more volatile environment remains to be seen.
